Serial urinary IL-2, IL-6, IL-8, TNFα, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG

Anticancer Research

Volumn 21, Issue 4 B, 2001, Pages 3041-3047

  Sanchez Carbayo M ^a   Urrutia, M ^a   Romani, R ^a   Herrero, M ^a   Gonzalez De Buitrago, J M ^a   Navajo, J A ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Bladder neoplasm; Cytokeratin and NMP22; Cytokine; TNF ; Urine

Indexed keywords

BCG VACCINE; CYTOKERATIN 19 FRAGMENT; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; NUCLEAR MATRIX PROTEIN FRAGMENT; NUCLEAR PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; MALE; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; URINALYSIS; URINARY TRACT INFECTION; URINE LEVEL;

ADMINISTRATION, INTRAVESICAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYTOKINES; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; INTERLEUKIN-6; INTERLEUKIN-8; KERATINS; MITOMYCIN; NEOPLASM PROTEINS; NUCLEAR PROTEINS; THIOTEPA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 0035160605     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors
2. Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer
3. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG
4. Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma
5. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin
6. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer
7. BCG treatment and the importance of an inflammatory response
8. The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy
9. Detection of urinary interleukin-2, interleukin-2 receptor, and tumor necrosis factor levels in patients with superficial bladder tumors after intravesical BCG immunotherapy
10. Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guerin immunotherapy
11. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy
12. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value
13. Evaluation of local immune response after intravesical bacille Calmette-Guerin treatment for superficial bladder cancer
14. Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer
15. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: A potential prognostic factor of tumor recurrence and progression
16. Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients
17. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: Statistically weighted syndrome analysis
18. Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10
19. Systemic immune response after intravesical instillation of bacille Calmette-Guerin (BCG) for superficial bladder cancer
20. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: Can it predict the optimal number of instillations?
21. Prognostic factors and therapy for superficial and invasive bladder cancer
22. Initial evaluation of UBC as a tumor marker for bladder cancer
23. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma
24. New electrochemiluminiscent immunoassay for the determination of CYFRA 21-1: Analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer
25. Use a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment
26. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder
27. Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer
28. Evaluation of NMP22 as a tumor marker in the detection of transitional cell carcinoma of the bladder
29. Staging of cancer at genitourinary sites
30. Urinary interleukins in patients receiving intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer
31. Local continuous high dose interleukin 2: A new therapeutic model for the treatment of advanced bladder carcinoma
32. Differential immuno-suppresive effects of metabolic inhibitors on T-lymphocite activation
33. Tumor-associated eosinophilia in interleukin-2-treated patients: Evidence of toxic eosinophil degranulation on bladder cancer cells
34. A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer